Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker TNGX
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 5,000 | $25.00 | $125.0K Sale | Form 4 ↗ |
| Nov 2, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 1,100 | $22.99 | $25.3K Sale | Form 4 ↗ |
| Nov 2, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 3,900 | $22.26 | $86.8K Sale | Form 4 ↗ |
| Nov 2, 2026 | Jessica Newcomb Principal Accounting Officer | TNGX Tango Therapeutics, Inc. | Sale | 1,460 | $22.98 | $33.6K Sale | Form 4 ↗ |
| Nov 2, 2026 | Jessica Newcomb Principal Accounting Officer | TNGX Tango Therapeutics, Inc. | Sale | 5,571 | $22.28 | $124.1K Sale | Form 4 ↗ |
| Sep 22, 2026 | Jessica Newcomb Principal Accounting Officer | TNGX Tango Therapeutics, Inc. | Sale | 2,400 | $25.17 | $60.4K Sale | Form 4 ↗ |
| Sep 22, 2026 | Jessica Newcomb Principal Accounting Officer | TNGX Tango Therapeutics, Inc. | Sale | 5,100 | $23.97 | $122.2K Sale | Form 4 ↗ |
| Sep 22, 2026 | Jessica Newcomb Principal Accounting Officer | TNGX Tango Therapeutics, Inc. | Sale | 700 | $22.80 | $16.0K Sale | Form 4 ↗ |
| Sep 1, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 27,000 | $22.37 | $604.0K Sale | Form 4 ↗ |
| Aug 3, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 21,733 | $27.35 | $594.4K Sale | Form 4 ↗ |
| Aug 3, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 5,267 | $26.79 | $141.1K Sale | Form 4 ↗ |
| Jul 1, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 7,371 | $30.25 | $223.0K Sale | Form 4 ↗ |
| Jul 1, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 19,629 | $29.34 | $575.9K Sale | Form 4 ↗ |
| Jun 1, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 20,860 | $23.06 | $481.0K Sale | Form 4 ↗ |
| Jun 1, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 6,140 | $22.25 | $136.6K Sale | Form 4 ↗ |
| May 1, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 1,100 | $22.00 | $24.2K Sale | Form 4 ↗ |
| May 1, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 25,900 | $21.19 | $548.8K Sale | Form 4 ↗ |
| Apr 15, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 38,460 | $25.00 | $961.5K Sale | Form 4 ↗ |
| Apr 1, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 27,000 | $21.20 | $572.4K Sale | Form 4 ↗ |
| Mar 25, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 12,000 | $20.11 | $241.3K Sale | Form 4 ↗ |
| Mar 5, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 20,251 | $15.00 | $303.8K Sale | Form 4 ↗ |
| Feb 25, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 54,345 | $12.77 | $694.0K Sale | Form 4 ↗ |
| Feb 3, 2026 | Daniella Beckman Chief Financial Officer | TNGX Tango Therapeutics, Inc. | Sale | 113 | $12.90 | $1,458 Sale | Form 4 ↗ |
| Feb 3, 2026 | Daniella Beckman Chief Financial Officer | TNGX Tango Therapeutics, Inc. | Sale | 10,204 | $12.26 | $125.1K Sale | Form 4 ↗ |
| Feb 3, 2026 | Barbara Weber Director, Executive Chair, Director | TNGX Tango Therapeutics, Inc. | Sale | 333 | $12.90 | $4,296 Sale | Form 4 ↗ |
| Feb 3, 2026 | Barbara Weber Director, Executive Chair, Director | TNGX Tango Therapeutics, Inc. | Sale | 30,186 | $12.26 | $370.1K Sale | Form 4 ↗ |
| Feb 3, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 201 | $12.90 | $2,593 Sale | Form 4 ↗ |
| Feb 3, 2026 | Adam Crystal President, R&D | TNGX Tango Therapeutics, Inc. | Sale | 18,251 | $12.26 | $223.8K Sale | Form 4 ↗ |
| Oct 23, 2025 | TRV GP IV, LLC 10% owner | TNGX Tango Therapeutics, Inc. | Sale | 477,401 | $10.15 | $4.8M Sale | Form 4 ↗ |
| Sep 25, 2025 | TRV GP IV, LLC 10% owner | TNGX Tango Therapeutics, Inc. | Sale | 500,000 | $8.02 | $4.0M Sale | Form 4 ↗ |
| Sep 16, 2025 | TRV GP IV, LLC 10% owner | TNGX Tango Therapeutics, Inc. | Sale | 363,541 | $7.04 | $2.6M Sale | Form 4 ↗ |
| Sep 8, 2025 | TRV GP IV, LLC 10% owner | TNGX Tango Therapeutics, Inc. | Sale | 86,459 | $7.04 | $608.7K Sale | Form 4 ↗ |
| Sep 5, 2025 | TRV GP IV, LLC 10% owner | TNGX Tango Therapeutics, Inc. | Sale | 642,906 | $7.00 | $4.5M Sale | Form 4 ↗ |
| Aug 22, 2025 | Third Rock Ventures GP IV, L.P. 10% owner | TNGX Tango Therapeutics, Inc. | Sale | 302,194 | $7.00 | $2.1M Sale | Form 4 ↗ |
| Aug 19, 2025 | Third Rock Ventures GP IV, L.P. 10% owner | TNGX Tango Therapeutics, Inc. | Sale | 1.10M | $7.01 | $7.7M Sale | Form 4 ↗ |
| Feb 5, 2025 | Douglas Barry General Counsel | TNGX Tango Therapeutics, Inc. | Sale | 2,556 | $3.16 | $8,077 Sale | Form 4 ↗ |
| Feb 5, 2025 | Daniella Beckman Chief Financial Officer | TNGX Tango Therapeutics, Inc. | Sale | 3,948 | $3.16 | $12.5K Sale | Form 4 ↗ |
| Feb 5, 2025 | Adam Crystal See Remarks | TNGX Tango Therapeutics, Inc. | Sale | 6,851 | $3.16 | $21.6K Sale | Form 4 ↗ |
| Feb 5, 2025 | Barbara Weber Chief Executive Officer, Director | TNGX Tango Therapeutics, Inc. | Sale | 9,013 | $3.16 | $28.5K Sale | Form 4 ↗ |
| Feb 4, 2025 | Douglas Barry General Counsel | TNGX Tango Therapeutics, Inc. | Sale | 2,774 | $2.99 | $8,294 Sale | Form 4 ↗ |
| Feb 4, 2025 | Daniella Beckman Chief Financial Officer | TNGX Tango Therapeutics, Inc. | Sale | 4,284 | $2.99 | $12.8K Sale | Form 4 ↗ |
| Feb 4, 2025 | Adam Crystal See Remarks | TNGX Tango Therapeutics, Inc. | Sale | 7,432 | $2.99 | $22.2K Sale | Form 4 ↗ |
| Feb 4, 2025 | Barbara Weber Chief Executive Officer, Director | TNGX Tango Therapeutics, Inc. | Sale | 9,778 | $2.99 | $29.2K Sale | Form 4 ↗ |
| Nov 18, 2024 | Mace Rothenberg Director | TNGX Tango Therapeutics, Inc. | Buy | 10,000 | $3.78 | $37.8K Buy | Form 4 ↗ |
| Nov 14, 2024 | Mace Rothenberg Director | TNGX Tango Therapeutics, Inc. | Buy | 10,000 | $3.62 | $36.2K Buy | Form 4 ↗ |
| Nov 7, 2024 | EcoR1 Capital, LLC 10% owner | TNGX Tango Therapeutics, Inc. | Sale | 1.14M | $2.92 | $3.3M Sale | Form 4 ↗ |
| Nov 7, 2024 | EcoR1 Capital, LLC 10% owner | TNGX Tango Therapeutics, Inc. | Sale | 62,318 | $3.29 | $205.0K Sale | Form 4 ↗ |
| Nov 6, 2024 | EcoR1 Capital, LLC 10% owner | TNGX Tango Therapeutics, Inc. | Sale | 1.49M | $3.28 | $4.9M Sale | Form 4 ↗ |
| Nov 6, 2024 | Boxer Capital Management, LLC | TNGX Tango Therapeutics, Inc. | Sale | 3.08M | $3.14 | $9.7M Sale | Form 4 ↗ |
| Oct 25, 2024 | Boxer Capital Management, LLC | TNGX Tango Therapeutics, Inc. | Sale | 633,000 | $6.87 | $4.3M Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:34 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances